Global pharma major Lupin Limited (Lupin) today announced the appointment of Spiro Gavaris as President U.S. Generics business. As part of Lupin's senior leadership team, Spiro will be responsible for the overall strategy, implementation and growth of Lupin's U.S. Generics business.
Spiro joins Lupin with significant experience in the branded, generic and biotech industries. He most recently served as President of Specialty Generics business at Mallinckrodt Pharmaceuticals and the President of US Injectables at Hikma.
Commenting on the appointment, Vinita Gupta, CEO, Lupin said, "Spiro brings strong pharma and biotech experience and has an established track record of success in building generics business across platforms, and in particular on the injectables front. We are delighted to welcome him to our leadership team."
Shares of Lupin Limited was last trading in BSE at Rs. 754.55 as compared to the previous close of Rs. 769.75. The total number of shares traded during the day was 16017 in over 1161 trades.
The stock hit an intraday high of Rs. 772.50 and intraday low of 752.90. The net turnover during the day was Rs. 12167643.00.